Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia

Mark A DEEG; John B BUSE; Ronald B GOLDBERG; David M KENDALL; Anthony J ZAGAR; Scott J JACOBER; Mehmood A KHAN; Alfonzo T PEREZ; Meng H TAN

doi:10.2337/dc06-1903

Back

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia

Journal article

Open access

Peer reviewed

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia

Mark A DEEG, John B BUSE, Ronald B GOLDBERG, David M KENDALL, Anthony J ZAGAR, Scott J JACOBER, Mehmood A KHAN, Alfonzo T PEREZ and Meng H TAN

Diabetes care, Vol.30(10), pp.2458-2464

2007

DOI: https://doi.org/10.2337/dc06-1903

PMID: 17595355

Abstract

Public health. Hygiene-occupational medicine

Public health. Hygiene

Diabetes. Impaired glucose tolerance

Miscellaneous

Biological and medical sciences

Endocrinopathies

Etiopathogenesis. Screening. Investigations. Target tissue resistance

Metabolic diseases

Medical sciences

Endocrine pancreas. Apud cells (diseases)

Files and links (1)

url

https://doi.org/10.2337/dc06-1903View

Published (Version of record) Open

Metrics

9 Record Views

162 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.26 Diabetes; 1.26.831 GLP-1
Web Of Science research areas: Endocrinology & Metabolism
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Creators: Mark A DEEG - Department of Endocrinology and Metabolism, Veterans Affairs Hospital and Indiana University, Indianapolis, Indiana, United States
John B BUSE - Department of Endocrinology and General Medicine, University of North Caro lina, Chapel Hill, North Carolina, United States
Ronald B GOLDBERG - Department of Endocrinology, Metabolism and Diabetes, University of Miami, Miami, Florida, United States
David M KENDALL - International Diabetes Center, Park Nicollet Institute, Minneapolis, Minnesota, United States
Anthony J ZAGAR - Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
Scott J JACOBER - Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
Mehmood A KHAN - Takeda Pharmaceuticals North America, Lincolnshire, Illinois, United States
Alfonzo T PEREZ - Takeda Global Research and Development, Lincolnshire, Illinois, United States
Meng H TAN - Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States
Publication Details: Diabetes care, Vol.30(10), pp.2458-2464
Publisher: American Diabetes Association; Alexandria, VA
Academic Unit: Miller School of Medicine; Diabetes Research Institute (DRI)
Language: English
Resource Type: Journal article
PMID: 17595355
Record Identifier: 991031576518402976